These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 31526390)

  • 1. Diagnostic extended usefulness of RMI: comparison of four risk of malignancy index in preoperative differentiation of borderline ovarian tumors and benign ovarian tumors.
    Zhang S; Yu S; Hou W; Li X; Ning C; Wu Y; Zhang F; Jiao YF; Lee LTO; Sun L
    J Ovarian Res; 2019 Sep; 12(1):87. PubMed ID: 31526390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of risk of malignancy index (RMI), CA125, CA 19-9, ultrasound score, and menopausal status in borderline ovarian tumor.
    Alanbay I; Akturk E; Coksuer H; Ercan M; Karaşahin E; Dede M; Yenen MC; Ozan H; Baser I
    Gynecol Endocrinol; 2012 Jun; 28(6):478-82. PubMed ID: 22122561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of risk of malignancy indices; RMI 1-4 in borderline ovarian tumor.
    Yenen MC; Alanbay I; Aktürk E; Ercan CM; Coksuer H; Karaşahin E; Ozan H; Dede M
    Eur J Gynaecol Oncol; 2012; 33(2):168-73. PubMed ID: 22611957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass.
    Karlsen MA; Sandhu N; Høgdall C; Christensen IJ; Nedergaard L; Lundvall L; Engelholm SA; Pedersen AT; Hartwell D; Lydolph M; Laursen IA; Høgdall EV
    Gynecol Oncol; 2012 Nov; 127(2):379-83. PubMed ID: 22835718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of pelvic masses score (PMS) and Risk of Malignancy Index (RMI 3) in the evaluation of pelvic masses.
    Rossi A; Forzano L; Romanello I; Ambrosini G; Iuri V; Marchesoni D
    Eur J Gynaecol Oncol; 2014; 35(4):421-4. PubMed ID: 25118484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of ultrasound score, CA125, menopausal status, and risk of malignancy index in differentiating between benign and borderline or malignant ovarian tumors.
    Leelahakorn S; Tangjitgamol S; Manusirivithaya S; Thongsuksai P; Jaroenchainon P; Jivangkul C
    J Med Assoc Thai; 2005 Oct; 88 Suppl 2():S22-30. PubMed ID: 17718292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subjective assessment by ultrasound is superior to the risk of malignancy index (RMI) or the risk of ovarian malignancy algorithm (ROMA) in discriminating benign from malignant adnexal masses.
    Van Gorp T; Veldman J; Van Calster B; Cadron I; Leunen K; Amant F; Timmerman D; Vergote I
    Eur J Cancer; 2012 Jul; 48(11):1649-56. PubMed ID: 22226481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pre-operative evaluation of ovarian tumors by risk of malignancy index, CA125 and ultrasound.
    Arun-Muthuvel V; Jaya V
    Asian Pac J Cancer Prev; 2014; 15(6):2929-32. PubMed ID: 24761927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the predictive performance of risk of malignancy indexes 1-4, HE4 and risk of malignancy algorithm in the triage of adnexal masses.
    Hada A; Han LP; Chen Y; Hu QH; Yuan Y; Liu L
    J Ovarian Res; 2020 Apr; 13(1):46. PubMed ID: 32334618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicenter clinical trial validating the performance of HE4, CA125, risk of ovarian malignancy algorithm and risk of malignancy index.
    Lycke M; Kristjansdottir B; Sundfeldt K
    Gynecol Oncol; 2018 Oct; 151(1):159-165. PubMed ID: 30149898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of CA125, HE4, risk ovarian malignancy algorithm (ROMA), and risk malignancy index (RMI) for the classification of ovarian masses.
    Anton C; Carvalho FM; Oliveira EI; Maciel GA; Baracat EC; Carvalho JP
    Clinics (Sao Paulo); 2012; 67(5):437-41. PubMed ID: 22666786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of two malignancy risk indices based on serum CA125, ultrasound score and menopausal status in the diagnosis of ovarian masses.
    Morgante G; la Marca A; Ditto A; De Leo V
    Br J Obstet Gynaecol; 1999 Jun; 106(6):524-7. PubMed ID: 10426607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The risk of malignancy index (RMI) in diagnosis of ovarian malignancy.
    Moolthiya W; Yuenyao P
    Asian Pac J Cancer Prev; 2009; 10(5):865-8. PubMed ID: 20162854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of malignancy index used as a diagnostic tool in a tertiary centre for patients with a pelvic mass.
    Håkansson F; Høgdall EV; Nedergaard L; Lundvall L; Engelholm SA; Pedersen AT; Hartwell D; Høgdall C;
    Acta Obstet Gynecol Scand; 2012 Apr; 91(4):496-502. PubMed ID: 22229703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel diagnostic index combining HE4, CA125 and age may improve triage of women with suspected ovarian cancer - An international multicenter study in women with an ovarian mass.
    Karlsen MA; Høgdall EV; Christensen IJ; Borgfeldt C; Kalapotharakos G; Zdrazilova-Dubska L; Chovanec J; Lok CA; Stiekema A; Mutz-Dehbalaie I; Rosenthal AN; Moore EK; Schodin BA; Sumpaico WW; Sundfeldt K; Kristjansdottir B; Zapardiel I; Høgdall CK
    Gynecol Oncol; 2015 Sep; 138(3):640-6. PubMed ID: 26086566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HE4, CA125, the Risk of Malignancy Algorithm and the Risk of Malignancy Index and complex pelvic masses - a prospective comparison in the pre-operative evaluation of pelvic masses in an Australian population.
    Richards A; Herbst U; Manalang J; Pather S; Saidi S; Tejada-Berges T; Tan K; Williams P; Carter J
    Aust N Z J Obstet Gynaecol; 2015 Oct; 55(5):493-7. PubMed ID: 26172511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the Copenhagen Index versus ROMA for the preoperative assessment of women with ovarian tumors.
    Minar L; Felsinger M; Cermakova Z; Zlamal F; Bienertova-Vasku J
    Int J Gynaecol Obstet; 2018 Feb; 140(2):241-246. PubMed ID: 29086914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of a risk of malignancy index based on serum CA125, ultrasound findings and menopausal status in the pre-operative diagnosis of pelvic masses.
    Tingulstad S; Hagen B; Skjeldestad FE; Onsrud M; Kiserud T; Halvorsen T; Nustad K
    Br J Obstet Gynaecol; 1996 Aug; 103(8):826-31. PubMed ID: 8760716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of protein biomarkers for preoperative differential diagnosis between benign and malignant ovarian tumors.
    Landolfo C; Achten ETL; Ceusters J; Baert T; Froyman W; Heremans R; Vanderstichele A; Thirion G; Van Hoylandt A; Claes S; Oosterlynck J; Van Rompuy AS; Schols D; Billen J; Van Calster B; Bourne T; Van Gorp T; Vergote I; Timmerman D; Coosemans A
    Gynecol Oncol; 2020 Dec; 159(3):811-819. PubMed ID: 32994054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discriminative value of CA-125, HE4, Risk of Malignancy Index II (RMI-II) and Risk of Malignancy Algorithm (ROMA) in the differential diagnosis of pelvic masses: conclusions from a referral Centre in Portugal.
    Melo Â; Veríssimo R; Farinha M; Martins NN; Martins FN
    J Obstet Gynaecol; 2018 Nov; 38(8):1140-1145. PubMed ID: 29884096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.